Ann: Lyell McEwin Hospital approved to join PharmAust trial, page-112

PAA is definitely the most exciting and novel Cancer drug company on the ASX.

Pitneys lead drug PPL1 has been able to show reductions in key Cancerous Tumor Markers in its ongoing Phase I human trials.
Excitingly, the drug, Monepantel,  is a new class of anti-cancer and it's the first time it's ever been used in humans.
The amazing part about the great news was the fact that PAA were doing a preliminary safety study on PPL1 (Phase 1) and yet the drug at its lowest dose was able to show a marked reduction of between 8% and 65% in 4 out of 4 patients taking part in the trial.

Of further great importance is the fact that all participants in the trial are terminal cancer patients with not long to live suffering from aggressive forms of cancer and have failed other standards of care, so PAA and it's PPL1 is trying to treat the WORST of the WORST Cancer for which there's is no hope or cure.

If they can continue to demonstrate these results with larger sample sizes, this company will be worth a ridiculous amount of money.
Recent targeted drug therapies such as Herceptin and Avastin have reached over $6billion in annual sales and these drugs are not without serious side effects and toxicity. The fact that PAA's drug, Monepantel, has widely been used in animals means that this is a drug which is highly unlikely to present any significant toxic effects in humans (Unlike Herceptin and Avastin).

A chemotherapeutic agent such as this DOES NOT EXIST in our society. This drug could completely revolutionise the oncology world and the world of those patient's suffering from this terrible disease.

It's only early stages, but it's only capped at $20mill... there is no way that this company won't increase atleast 5-fold from here.